MedTrace Logo

Characterization of the Adherence Threshold for HIV Suppression of a Kaletra-based Regimen

NCT00200369 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2009-11-05

No results posted yet for this study

Summary

The hypothesis of this study is that the level of adherence necessary to achieve HIV virologic suppression with a ritonavir boosted protease inhibitor regimen (i.e. lopinavir/ritonavir) is less than the 95% rate observed in the published literature with unboosted regimens.

Conditions

  • HIV Infection

Interventions

DEVICE

MEMS cap

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Montefiore Medical Center

    lead OTHER

Principal Investigators

  • Jonathan Shuter, MD · Montefiore Medical Center

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Completion
2006-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00200369 on ClinicalTrials.gov